Navigation Links
Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
Date:4/3/2013

RARITAN, N.J., April 3, 2013 /PRNewswire/ -- Veridex, LLC (Veridex) announced today that the first study of the company's next-generation circulating tumor cell (CTC) technology, developed in collaboration with researchers at Massachusetts General Hospital (MGH), has been published in Science Translational Medicine.  The collaboration, initially announced in January 2011, has led to the development of a next-generation CTC (or "liquid biopsy") technology that offers enhanced specificity and sensitivity and enables more extensive characterization of captured cells.

The new technology tests for CTCs from the blood of cancer patients using advanced microfluidic separation techniques integrated with innovative magnetic sorting to isolate a broad spectrum of rare circulating cancer cells. This technology will allow physicians to get information about a patient's cancer at the time treatment is being administered, one of the key components to enabling personalized medicine.

Results from the in vitro study showed the integrated system enabled the processing of large blood volumes with high throughput and efficiency, and also allowed for the ability to isolate CTCs from both epithelial and non-epithelial cancers.

In the study, the technology was used to identify the presence of CTCs in patients with cancers of the lung, prostate, pancreas, breast, as well as melanoma.

"Veridex is proud to have introduced CELLSEARCH®, the first and only FDA-cleared CTC test, and we're excited to work with the team at Massachusetts General Hospital on our next-generation test," said Nicholas C. Dracopoli , Ph.D., Vice President and Head of Oncology Biomarkers, Janssen Research & Development, LLC.  "Together, Veridex and the MGH team bring more than 25 years of experience in rare cell technology to this project. We're encouraged by the positive results from
'/>"/>

SOURCE Veridex, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innovative Research Collaboration to Advance Next-Generation Methods in Peptide Discovery for Cosmeceuticals
2. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
3. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
4. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
5. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
6. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
7. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
8. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
9. Remedy Informatics to Debut SpecimenTrack, Next-Generation Biorepository Software at ISBER 2012 Annual Meeting
10. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
11. The Miami Neuroscience Center at Larkin ofrece esperanza a los diagnosticados con tumores cerebrales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and LYON, France , Dec. ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ... developing an ultra-rapid insulin, known as BioChaperone Lispro, for ... diabetes. BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology ... Lilly and Adocia will develop BioChaperone Lispro with the ...
(Date:12/17/2014)... , December 17, 2014 Revenue and ... expenditure on research and development In the past ... revenue by two percent to EUR 4.287 billion (last year: ... by 14 percent to EUR 360 million. "Overall, 2013/14 was ... Michael Kaschke , President and CEO of Carl Zeiss ...
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... R.I., Dec. 23, 2010 A new ... journal articles about the impact of health information technology ... while there is evidence to suggest that simple electronic ... adherence, there are few studies that show how HIT ...
... IBA Particle Therapy, the worldwide leader in proton therapy, ... grant to Compass to Care Childhood Cancer Foundation, a ... and CEO of Compass to Care, this financial support ... when traveling to proton treatment centers for their child ...
Cached Medicine Technology:New CVS Caremark Study Finds Health Information Technology May Help Promote Adherence, But More Information and Direction Needed 2New CVS Caremark Study Finds Health Information Technology May Help Promote Adherence, But More Information and Direction Needed 3IBA Particle Therapy's $20,000 Grant Helps Non-Profit Ease Costs for Children Traveling to Receive Proton Therapy 2
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/19/2014)... 20, 2014 Today, Balfleet.com , ... outfits, announces its formal dress promotion. All the old ... to 60% off. , Balfleet.com is well-known for its ... dresses, prom dresses, cocktail dresses and more. Its formal ... money-back guarantee, and they can create an elegant look ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... 19, 2014 Eufaula, Oklahoma, located just ... Eufaula, the state’s largest lake with more than 600 ... home to a little more than 3,000 residents, hosted ... Saturday, the 6th of December. , Featuring Santa, Christmas ... downtown Eufaula on Main Street. Narconon Arrowhead’s parade ...
(Date:12/19/2014)... December 20, 2014 The print component ... and Business subscription of the Toronto Star, with a ... of 622,169. The digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... . , The publication features an exclusive interview ...
Breaking Medicine News(10 mins):Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2
... Service Corporation,s Technology Investments Streamline ... HealthLeaders-InterStudy, NASHVILLE, Tenn., Aug. 5 ... intelligence, reports that Health,Care Service Corporation is ... serve its members. According to the,new report ...
... (Nasdaq: NKTR ) today announced the company,s financial ... 2008., Cash, cash equivalents, and short-term investments were ... at March 31, 2008., Revenue for the three ... to revenue of $65.9 million in the second quarter ...
... 6 Nektar,Therapeutics (Nasdaq: NKTR ) today ... the position of Senior Vice President of Drug,Development ... Dr.,Moreadith will report to Nektar,s President and Chief ... lead Clinical Drug Development, Clinical,Pharmacology and Toxicology, and ...
... 9.3 percent (constant currency) - Execution of strategic ... guidance based on year-to-date ... performance and operational momentum, BATESVILLE, Ind., Aug. 6 ... results for its fiscal,third quarter ended June 30, 2008 -- ...
... Pa., Aug. 6 West Pharmaceutical,Services, Inc. (NYSE: ... Vice,President and Chief Financial Officer, and Michael Anderson, ... will be presenting at,the CJS Securities 8th Annual ... NY, on August 12, 2008. A copy of ...
... A drug-like molecule called Wnt can be substituted for ... to adult cells to reprogram them to an embryonic-stem-cell-like ... embryonic stem-cell-like cells, known as induced pluripotent (IPS) cells, ... diabetes. , Demonstrated in mice, the elimination of ...
Cached Medicine News:Health News:Insurance Giant Leverages Technology to Enhance Offerings 2Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 2Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 3Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 4Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 5Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 6Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 7Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 8Health News:Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer 2Health News:Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer 3Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 2Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 3Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 4Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 5Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 6Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 7Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 8Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 9Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 10Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 11Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 12Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 13Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 14Health News:Recipe for cell reprogramming adds protein 2
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. All SheerVision ...
... Experience the finest surgical-quality loupes available ... the standard for innovative optical design, ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. Make both ...
... SheerVision have addressed a key need of ... with light-weight comfort for everyday use. ... as 1.5 ounces when included with a ... either a flip-up or through-the-lens (TTL) design. ...
Medicine Products: